Biomarkers of brain amyloidosis and neurodegeneration/synaptic dysfunction are featured in recent diagnostic criteria for Alzheimer's disease. Several gaps in our knowledge, however, need to be filled before they can be adopted clinically. The aim of this article is to describe a roadmap, developed by a multidisciplinary task force, to rationally implement biomarkers for Italian Memory Clinics. This roadmap is based on a framework comprising 5 sequential phases: identification of leads for potentially useful biomarkers; development of clinical assays for clinical disease; evaluation of detection of early stages; definition of operating characteristics in relevant populations; and estimation of reducing disease-associated mortality, morbidity, and disability. The roadmap was devised by identifying current evidence of validity, still missing evidence, and action needed to collect this missing evidence. With appropriate adaptation to local, country-specific circumstances, the roadmap can be translated to other countries.

Frisoni, G., Perani, D., Bastianello, S., Bernardi, G., Porteri, C., Boccardi, M., et al. (2017). Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap. NEUROBIOLOGY OF AGING, 52, 119-131 [10.1016/j.neurobiolaging.2016.02.033].

Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap

TRABUCCHI, MARCO MARIO;
2017-01-01

Abstract

Biomarkers of brain amyloidosis and neurodegeneration/synaptic dysfunction are featured in recent diagnostic criteria for Alzheimer's disease. Several gaps in our knowledge, however, need to be filled before they can be adopted clinically. The aim of this article is to describe a roadmap, developed by a multidisciplinary task force, to rationally implement biomarkers for Italian Memory Clinics. This roadmap is based on a framework comprising 5 sequential phases: identification of leads for potentially useful biomarkers; development of clinical assays for clinical disease; evaluation of detection of early stages; definition of operating characteristics in relevant populations; and estimation of reducing disease-associated mortality, morbidity, and disability. The roadmap was devised by identifying current evidence of validity, still missing evidence, and action needed to collect this missing evidence. With appropriate adaptation to local, country-specific circumstances, the roadmap can be translated to other countries.
2017
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/14 - FARMACOLOGIA
English
Con Impact Factor ISI
Alzheimer; Biomarkers; Diagnosis; Validation;
Frisoni, G., Perani, D., Bastianello, S., Bernardi, G., Porteri, C., Boccardi, M., et al. (2017). Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap. NEUROBIOLOGY OF AGING, 52, 119-131 [10.1016/j.neurobiolaging.2016.02.033].
Frisoni, G; Perani, D; Bastianello, S; Bernardi, G; Porteri, C; Boccardi, M; Cappa, S; Trabucchi, Mm; Padovani, A
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/171316
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 24
social impact